“I have been constantly impressed not only with the CHRISTUS Stehlin Foundation’s rich legacy of transformative research, but also the tenacious commitment of foundation staff to the vision of Dr. Stehlin. A connection between this vision and the mission of our sponsoring congregations was immediately clear, as both seek not only to treat illness, but also honor the dignity inherent in every person.”
Tom Royer, M.D.,
CEO Emeritus, CHRISTUS Health, 2011
The cancer drug bexarotene quickly eliminates Alzheimer's disease-associated amyloid beta from the brain and reverses memory problems in mice, a new study finds. The results suggest that bexarotene could help the 5.4 million Americans with Alzheimer's disease.
An international research team has made a breakthrough that could change the way pediatric cancers are treated in the future. The researchers identified two genetic mutations responsible for up to 40 per cent of glioblastomas in children.